Year To Quarter End Consolidated Statement Of Income

COSMOS Pharmaceutical Corporation - Filing #7341374

Concept 2023-06-01 to
2024-02-29
2022-06-01 to
2023-02-28
Year to quarter end consolidated statement of income
Statement of income
Net sales
715,311,000,000 JPY
606,302,000,000 JPY
Cost of sales
575,647,000,000 JPY
481,993,000,000 JPY
Gross profit (loss)
139,664,000,000 JPY
124,309,000,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
115,925,000,000 JPY
102,142,000,000 JPY
Operating profit (loss)
23,738,000,000 JPY
22,167,000,000 JPY
Non-operating income
Interest income
33,000,000 JPY
35,000,000 JPY
Non-operating income
2,758,000,000 JPY
2,717,000,000 JPY
Non-operating expenses
Interest expenses
53,000,000 JPY
34,000,000 JPY
Non-operating expenses
583,000,000 JPY
491,000,000 JPY
Ordinary profit (loss)
25,914,000,000 JPY
24,393,000,000 JPY
Extraordinary income
Gain on sale of non-current assets
75,000,000 JPY
JPY
Extraordinary income
478,000,000 JPY
39,000,000 JPY
Extraordinary losses
Loss on disaster
10,000,000 JPY
4,000,000 JPY
Extraordinary losses
450,000,000 JPY
199,000,000 JPY
Profit (loss) before income taxes
25,942,000,000 JPY
24,232,000,000 JPY
Income taxes
8,584,000,000 JPY
7,948,000,000 JPY
Profit (loss)
17,357,000,000 JPY
16,283,000,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
17,357,000,000 JPY
16,283,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
0 JPY
0 JPY
Remeasurements of defined benefit plans, net of tax
-3,000,000 JPY
7,000,000 JPY
Other comprehensive income
-2,000,000 JPY
7,000,000 JPY
Comprehensive income
17,354,000,000 JPY
16,291,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
17,354,000,000 JPY
16,291,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.